Company Overview of Prolong Pharmaceuticals, Inc.
Prolong Pharmaceuticals, Inc., a biotechnology and pharmaceutical manufacturing company, develops biopharmaceutical products for the treatment of anemia. The company focuses on sickle cell anemia, diabetic ischemia, and several trauma indications. Its products include SANGUINATE, an oxygen transfer agent to treat anemia; and protein therapeutics. The company was founded in 2002 and is based in South Plainfield, New Jersey.
300 Corporate Court
Middlesex Business Center
South Plainfield, NJ 07080
Founded in 2002
Key Executives for Prolong Pharmaceuticals, Inc.
Founder, Chief Executive Officer, Chief Scientific Officer and Director
Managing Director of Research and Development
Vice President of Information Services
Compensation as of Fiscal Year 2014.
Prolong Pharmaceuticals, Inc. Key Developments
Prolong Pharmaceuticals, Inc. Presents at The 2nd Annual Sachs Cancer Bio Partnering & Investment Forum, Mar-19-2014 04:15 PM
Mar 12 14
Prolong Pharmaceuticals, Inc. Presents at The 2nd Annual Sachs Cancer Bio Partnering & Investment Forum, Mar-19-2014 04:15 PM. Venue: New York Academy of Sciences, New York, United States.
Prolong Pharmaceuticals LLC Appoints Ronald G Jubin as Managing Director, Research and Development
Dec 19 13
Prolong Pharmaceuticals LLC named Ronald G Jubin, PhD as its managing director, Research and Development. The new managing director, Research and Development will be responsible for pre-clinical discovery, methods development and the advancement of the company's pipeline candidates.
Prolong Announces Encouraging Results from Phase I Hemolytic Disorder Study
Oct 9 13
Prolong Pharmaceuticals LLC, a biopharmaceutical company, has announced results from its Phase I study of the company's lead product, SANGUINATE. SANGUINATE (PEGylated carboxyhemoglobin bovine) is an intravenous therapeutic that combines the beneficial functions of a carbon monoxide releasing molecule (CORM) with an oxygen transfer agent (OTA) as well as acting as a plasma expander/flow enhancer. Results from animal studies indicate that low dose release of carbon monoxide promotes anti-inflammatory and anti-vasoconstriction effects, while oxygen is actively delivered to regions of low oxygen concentration (ischemia). The Phase I study was a single center, single-blind, placebo-controlled, single dose study of the safety, tolerability and pharmacokinetics of SANGUINATE in healthy subjects. Three dose levels of SANGUINATE (80 mg/kg, 120 mg/kg, and 160 mg/kg) were administered by intravenous infusion to 3 groups. Each group included 8 subjects: 6 subjects who received active treatment (SANGUINATE) and 2 subjects who received placebo comparator (saline). Overall, SANGUINATE was found to be well tolerated. There were no serious adverse events in this study and there were no discontinuations due to adverse events.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|